An A1c of 7.8%, Two Falls, and a Patient Who Wants Tighter Control
A 78-year-old man with type 2 diabetes for 16 years lives alone. He has mild cognitive impairment (MoCA 23/30) and an eGFR of 26 mL/min/1.73 m². His A1c is 7.8%. Current regimen: metformin 1000 mg twice daily, glyburide 10 mg daily, and insulin glargine 18 units at bedtime. In the past 5 weeks he has had two hypoglycemia episodes requiring assistance - one prompted a 911 call, and the other caused a fall with a distal radius fracture. He reports no warning symptoms before the lows and says his late wife 'used to catch them.' He has nonproliferative retinopathy and no cardiovascular events. Blood pressure is 148/82 mmHg, weight 68 kg. He asks, 'Isn't 7.8 too high? My other doctor wanted me under 7.'
1. Set his glycemic target and justify it against his competing risks.
Read the worked answer
Target A1c: less than 8.0% - and I would accept 8.0–8.5% if it buys freedom from lows.
The reasoning is a risk trade-off, not a number lookup:
- What tight control buys him: prevention of microvascular disease over 8–10 years. He already has retinopathy and an eGFR of 26; the kidney trajectory is now driven more by blood pressure and renin-angiotensin blockade than by A1c, and he has no cardiovascular disease to protect with intensive glucose lowering.
- What tight control costs him: severe hypoglycemia. At 78, with cognitive impairment, living alone, and an eGFR of 26, his counterregulatory response is blunted and his insulin and sulfonylurea clearance is reduced. He has already had two events requiring third-party help and a fracture in five weeks. Severe hypoglycemia in this population is associated with falls, fractures, dementia progression, arrhythmia, and death - harms that arrive now, whereas the microvascular benefit arrives years later.
- He has hypoglycemia unawareness, which converts every dosing error into an emergency rather than a learning event.
- A1c 7.8% may also understate his instability. An average can look acceptable while concealing wide swings; the priority question is not the mean but the variance and the depth of the troughs.
Explain it to him in his own terms: 'Under 7 is the right goal for a 50-year-old with healthy kidneys. For you, the bigger danger is another fall. We are going to aim a little higher on purpose.' Reframe the target as a safety decision rather than a lowering of standards.
2. Which medications do you change, and why? Address the sulfonylurea and the metformin specifically.
Read the worked answer
Stop glyburide. Stop metformin. Then rebuild the regimen around hypoglycemia avoidance.
- Glyburide - stop, do not merely reduce. It is a long-acting sulfonylurea whose active metabolites accumulate in renal impairment, producing prolonged, recurrent hypoglycemia that can outlast a bag of dextrose. This is the single most likely culprit for his severe events and it has no offsetting benefit here.
- Metformin - stop. Contraindicated at eGFR <30 due to lactic acidosis risk, and he has additional risk factors (age, possible dehydration during illness). If metformin has been continued mechanically, it needs to come off the list explicitly.
- Basal insulin - reduce, do not stop abruptly. With the sulfonylurea gone, his insulin requirement may fall. Cutting glargine by roughly 20% (to ~14 units) with instructions to titrate against fasting glucose avoids rebound hyperglycemia while reducing nocturnal risk. If he is eating inconsistently, a lower basal dose plus a simplified regimen is safer than a perfect one.
- What to add if he needs more coverage: a DPP-4 inhibitor such as linagliptin requires no renal dose adjustment and carries minimal hypoglycemia risk. SGLT2 inhibitors have attenuated glucose-lowering at this eGFR and add volume-depletion and genital infection risk in an older man living alone; a GLP-1 receptor agonist causes weight loss, which is undesirable at 68 kg in a man with cognitive impairment.
- Also address blood pressure (148/82) with an ACE inhibitor or ARB - that is where the kidney and cardiovascular benefit now lies, not in pushing A1c down.
The governing principle: every remaining agent should be one whose failure mode is hyperglycemia, not hypoglycemia.
3. Design the monitoring and safety plan, including what you teach him and any caregiver.
Read the worked answer
Monitoring must be matched to his deficits - he cannot be his own safety net.
- CGM rather than intermittent fingersticks: he has hypoglycemia unawareness and is insulin-treated. Continuous data will show overnight troughs, document the effect of the medication changes, and can alarm. If CGM is not feasible, a structured fingerstick schedule including a 3 a.m. check is the fallback.
- Glucagon prescription and training for whoever is with him; a neighbor or family member should know where it is kept. Confirm he can actually open and use it.
- Sick-day rules: hold the remaining glucose-lowering medication if he cannot eat; hydration plan; a written number to call.
- Driving and fall safety: check glucose before driving, treat if below 70 mg/dL or trending down, and recheck before starting. Review home hazards; a fall with a fracture is a leading indicator of the next one.
- Hypoglycemia treatment teaching: 15 g fast carbohydrate, recheck in 15 minutes, repeat if still low, then a snack with protein. Verify he has treatment within reach in the bedroom, not just the kitchen.
- Cognitive support: simplify to the fewest doses possible, use a pill organizer or blister pack, and involve a family member or a pharmacy synchronization program. Written instructions should be one page with large print.
- Follow-up: contact within 1–2 weeks to review the CGM or log, not 3 months. Recheck A1c at 3 months, and reassess the target then - if he is stable and free of lows, 7.5% may be achievable; if lows persist, loosen further.